P-Selectin Expression, but not GPIIb/IIIa Activation, is Enhanced in the Inflammatory Stage of Takayasu's Arteritis

Kasuya, Natsuko; Kishi, Yukio; Isobe, Mitsuaki; Yoshida, Masayuki; Numano, Fujío

doi:10.1253/circj.70.600

Cited by 28 publications

(12 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4] Endothelial cells are crucial regulators of vascular wall homeostasis and blood thrombogenicity; 5-7 the inflammatory cytokine tumor necrosis factor (TNF)-α has been shown to induce the expression of 2 TF isoforms: membrane-bound human "full length" TF (flTF), [8][9][10] and a soluble alternatively spliced human TF (asHTF). 6,10,11 Both TF isoforms circulate in blood.…”

mentioning

confidence: 99%

Role of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Regulating Alternative Splicing of Tissue Factor mRNA in Human Endothelial Cells

Eisenreich

Malz

Pepke

et al. 2009

Circ J

View full text Add to dashboard Cite

Background: Tissue factor (TF) is the primary initiator of blood coagulation. In response to tumor necrosis factor (TNF)-α human umbilical vein endothelial cells (HUVECs) express 2 TF isoforms: a soluble alternatively spliced isoform (asHTF) and membrane-bound "full length" (fl)TF. How the differential TF isoform expression is regulated is still unknown. This study compared the impact of PI3K/Akt pathway inhibition on alternative splicing of TF in HUVECs, to the influence of transcriptional regulation by inhibiting nuclear factor κ B (NFκB). Methods and Results:The mRNA expression of TF isoforms was assessed by real-time PCR, the thrombogenic activity was measured by a chromogenic TF activity assay and the phosphorylation state of serine/arginine-rich (SR) proteins was analyzed by western blotting. Transfection of HUVECs was done 72 h before the inhibition experiments were performed. PI3K/Akt pathway inhibition reduced the mRNA expression of asHTF but not flTF. Inhibition of NFκB reduced the expression of both isoforms. Moreover, the PI3K/Akt pathway inhibition, but not that of NFκB, modified the phosphorylation of the SR proteins SRp75, SRp55 and SF2/ASF. Additionally, overexpression of SF2/ASF and SRp75 influenced the differential TF-isoform expression in HUVECs. Conclusions: The PI3K/Akt pathway modulates alternative splicing of TF in HUVECs, distinct from transcriptional regulation. (Circ J 2009; 73: 1746 -1752

show abstract

mentioning

confidence: 99%

Role of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Regulating Alternative Splicing of Tissue Factor mRNA in Human Endothelial Cells

Eisenreich

Malz

Pepke

et al. 2009

Circ J

View full text Add to dashboard Cite

show abstract

“…La PCR aparenta relacionarse bien con la actividad de la (22)(23)(24)(25) enfermedad . Se describen otros marcadores como: activador tisular del plasminógeno, molécula de adhesión intercelular 1, molécula de adhesión vascular 1, selectina E, molécula de adhesión plaquetaria endotelial 1, anticuerpos anti-célula endotelial, anticuerpos anti-monocito, anticuerpos (26)(27)(28)(29)(30) dirigidos contra anexina V . (17) En el trabajo de Soto et al , la enfermedad aórtica generalizada (Tipo V) se encontró en 76 (69%) pacientes, la enfermedad tipo I estuvo presente en 21 (19%), tipo IIa en 3 (3%) mientras que tipo IIb en 4 (4%); Tipo III también se encontró en 4 casos (4%) y Tipo IV en 2 (2%).…”

Section: Discussionunclassified

Takayasu arteritis in a child: A case report

Morel

Marecos

Ávila

et al. 2017

Pediatr. (Asunción)

View full text Add to dashboard Cite

“…Low dose ASA has been observed to inhibit thrombosis in cardiovascular disease by inhibiting platelet activation and aggregation as well as improving endothelial dysfunction [30]. This protective mechanism may explain ASA's benefits in TAK as thromboxane B2 levels have been observed to increase in the affected limb of TAK patients and decrease in response to ASA treatment [31]- [33]. In GCA, the pathogenesis leading to occlusive events appears to be different.…”

Section: Discussionmentioning

confidence: 99%

The Use of Anti-Platelet and/or Anticoagulant Agents in the Prevention of Large Vessel Vasculitis-Associated Ischemic Complications: A Meta-Analysis

Jeong¹,

Barra²

2014

OJRA

View full text Add to dashboard Cite

Objective: To determine the effectiveness of antiplatelet and/or anticoagulant therapy (AP/AC) at reducing ischemic events in patients with Large Vessel Vasculitis (LVV). Methods: We performed a random effects meta-analysis of studies examining antiplatelet and/or anticoagulant therapy (AP/AC) and ischemic events in Takayasu's Arteritis (TAK) or Giant Cell Arteritis (GCA). Severe ischemic events were defined as stroke, ischemic ocular manifestations and claudication symptoms. Any ischemic event included jaw claudication in addition to the above manifestations. Results: Seven studies met inclusion criteria: 1 TAK and 6 GCA. The majority of patients (>80%) were treated with ASA and treatment was initiated prior to diagnosis of LVV. Risk of severe and any ischemic event in patients with LVV treated with AP/AC versus no treatment was not significantly different (OR 0.570, 95% CI 0.243, 1.340 and OR 0.594, 95% CI 0.248, 1.421, respectively). For studies with follow-up data (26-76 months), AP/AC was protective for severe ischemic events (OR 0.18, 95% CI 0.04, 0.83). Findings were similar when excluding studies that did not account for potential confounders, such as cardiovascular risk factors. Conclusion: At follow-up, antiplatelet therapy significantly decreases ischemic events in patients with LVV. However, in most cases of GCA, the treatment was initiated prior to the diagnosis of vasculitis. The benefit of initiating anti-platelet therapy at the time of GCA diagnosis remains unclear.

show abstract

P-Selectin Expression, but not GPIIb/IIIa Activation, is Enhanced in the Inflammatory Stage of Takayasu's Arteritis

Cited by 28 publications

References 41 publications

Role of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Regulating Alternative Splicing of Tissue Factor mRNA in Human Endothelial Cells

Role of the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway in Regulating Alternative Splicing of Tissue Factor mRNA in Human Endothelial Cells

Takayasu arteritis in a child: A case report

The Use of Anti-Platelet and/or Anticoagulant Agents in the Prevention of Large Vessel Vasculitis-Associated Ischemic Complications: A Meta-Analysis

Contact Info

Product

Resources

About